The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed di-MedSci.cn

The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed di

Chabane, M; Dioh, W; Dilda, P; Lafont, R; Veillet, S; Voit, T; Agus, S

NEUROMUSCULAR DISORDERS, 2019; 29 (): S92

科室
- - 订阅+
  - 更多科室
工具
服务